The observed increased risk of acute kidney injury with the GnRH antagonist degarelix is difficult to interpret as it was one of a number of analyses, based upon relatively few acute kidney injury events and because degarelix users are likely to have more advanced prostate cancer. The gene discussed is GNRH1; the disease is prostate carcinoma.